Pantakind 40 mg Tablet

Pantakind 40 mg Tablet   is contains active ingredient Pantoprazole (40mg) which belongs to proton pump inhibitor (PPI) class of drugs. It is prescribed to treat certain conditions like acidity, gastroesophageal reflux disease (Acid reflux),  heartburn, peptic ulcer disease, and Zollinger-Ellison syndrome.  

It works by reducing the amount of acid in the stomach which helps in relief of acid related indigestion & heartburn. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

• Acidity
• Treatment of Heartburn
• Gastroesophageal reflux disease (Acid reflux)
• Peptic ulcer disease
• Treatment of Zollinger-Ellison syndrome

Most side effects of Pantakind 40 mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Vomiting
• Nausea
• Diarrhea
• Abdominal pain
• Flatulence
• Headache

• The dosage and duration of the Pantakind 40 mg Tablet   are decided by the doctor based on the severity of the condition and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
• If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.   

• Pantakind 40 mg Tablet   is contains active ingredient  Pantoprazole (40mg) which is a proton pump inhibitor (PPI). It works by reducing the amount of acid in the stomach which helps in relief of acid related indigestion & heartburn.
• It irreversibly block the action of H+/K+-ATPase enzyme that is a proton pump, in the stomach's parietal cells which results in  effectively blocking the final step of acid production and significantly lowering stomach acidity.

• Richter, J. E., Bochenek, W., & Pantoprazole US GERD Study Group. (2000). Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Official journal of the American College of Gastroenterology| ACG, 95(11), 3071-3080.
• Dias, L. M. (2009). Pantoprazole: a proton pump inhibitor. Clinical drug investigation, 29(Suppl 2), 3-12.
• Röhss, K., Lind, T., & Wilder-Smith, C. (2004). Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. European journal of clinical pharmacology, 60(8), 531-539.
• Cheer, S. M., Prakash, A., Faulds, D., & Lamb, H. M. (2003). Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs, 63(1), 101-132.
• Poole, P. (2001). Pantoprazole. American journal of health-system pharmacy, 58(11), 999-1008.